The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy
- 24 January 2007
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 16 (5), 504-512
- https://doi.org/10.1002/pds.1356
Abstract
Purpose To evaluate whether the risk of coronary heart disease (CHD) differs among adult diabetic patients treated with thiazolidinediones (TZDs) and similar patients treated with combined oral metformin and sulfonylurea (M + S) therapy. Methods We conducted a retrospective cohort study involving 25 140 diabetic patients aged 18 and older who had at least one pharmacy claim for a TZD or combined M + S therapy between 1 January 1999 and 30 June 2002. We used propensity score matching to adjust for observable differences between initiators of combined M + S therapy and TZD initiators. The data were analyzed in two ways: first based on the original matched groups, ‘as balanced’, without accounting for switching to another medication during follow‐up, and second based on actual antidiabetic drug use during follow‐up, ‘as treated’. Cox proportional hazards regression and multivariable Poisson regression were performed to compare the risk of CHD events. Results In the ‘as balanced’ analysis, the risk for CHD among TZD users relative to combination drug users was close to the null value (adjusted hazard ratio: 1.02, 95% confidence intervals (CI): 0.87–1.20). In the ‘as treated’ analysis, the risk of CHD was similar for periods of current use of TZDs compared to periods of non‐use (incidence rate ratio: 1.10, 95%CI: 0.96–1.25). Conclusions These results do not suggest a cardioprotective or deleterious effects of TZDs compared with combined M + S oral therapy on the short‐term CHD event risk in persons with type 2 diabetes after accounting for the greater baseline CHD risk in TZD initiators. Copyright © 2007 John Wiley & Sons, Ltd.Keywords
This publication has 38 references indexed in Scilit:
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialThe Lancet, 2005
- Predictors of recall of over-the-counter and prescription non-steroidal anti-inflammatory drug exposurePharmacoepidemiology and Drug Safety, 2005
- Oral Antidiabetic AgentsDrugs, 2005
- Accuracy of medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital recordsAmerican Heart Journal, 2004
- Propensity score methods in drug safety studies: practice, strengths and limitationsPharmacoepidemiology and Drug Safety, 2001
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998
- Reducing Bias in Observational Studies Using Subclassification on the Propensity ScoreJournal of the American Statistical Association, 1984
- The central role of the propensity score in observational studies for causal effectsBiometrika, 1983